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Background: Xerosis is a common skin disorder frequently observed in diabetic patients. An effective hydration of
foot skin in diabetics is a relevant preventive strategy in order to maintain a healthy foot. Urea is considered an
effective hydrating and emollient topical product. The aim of the present study was to evaluate the efficacy of
topical urea 5% with arginine and carnosine (Ureadin Rx Db, ISDIN Spain) (UC) in comparison with glycerol-based
emollient topical product (Dexeryl, Pierre Fabre) (EC), in Type 2 diabetic patients.
Methods: We assessed the effect of UC on skin hydration in a randomized, evaluator-blinded comparative study in
40 type II diabetic patients, aged 40–75 years, treated with UC or the comparator for 28 days with a twice-daily
application. The principal outcomes were the Dryness Area Severity Index (DASI) Score and the Visual Analogue
Score (VAS) for skin dryness evaluated at baseline and at the end of study period by an investigator unaware of
treatment allocation.
Results: UC induced significantly greater hydration than EC with an 89% reduction in DASI score (from 1.6 to 0.2;
p < 0.001) in comparison with baseline values. After 4 weeks, compared with the control group, DASI score in UC
treated group was significantly lower (0.2 vs. 1.0; p = 0.048). VAS score (high values mean better hydration)
significantly increased in both groups during treatment. VAS score at the end of treatment period was significantly
higher in UC group in comparison with EC group (9.8 vs. 8.2; p = 0.05).
Conclusion: Application of urea 5%, arginine and carnosine cream increases skin hydration and alleviates the
condition of skin dryness in Type 2 diabetic patients in comparison with a control glycerol-based emollient product.
(Dutch Trials Register trial number 3328).
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Cutaneous complications are common in diabetes, with
approximately 30% of patients experiencing some skin
involvement during the course of their illness and these
may also be an early indicator of undiagnosed diabetes
[1]. In particular xerosis is a common skin disorder fre-
quently observed in diabetic patients [2]. Skin xerosis
and callous formation could be risk factors for diabetic
ulcers developing [3]. An effective hydration of foot skin
in diabetics is a relevant preventive strategy in order to
maintain a healthy foot [4]. Emollient and moisturizer
topical products are efficacious in repairing the epider-
mal barrier function and in ameliorating xerosis [5].
However few studies have been conducted in diabetic
patients assessing wheter this treatment can help correct
alterations in functional and mechanical properties of
diabetic skin. Urea is considered an effective hydrating
and emollient topical product [6]. Recent experimental
data performed in human keratinocytes suggest that
urea is not a simple emollient compound but it is able
to improve cell differentiation increasing gene expres-
sion of transglutaminase, filaggrin, aquaporin, and lori-
crin, therefore improving keratinocytes differentiation
[7]. Arginine is an important substrate for Nitric Oxide
formation [8]. In diabetic skin a deficit in NO produc-
tion has been demonstrated [9]. This reduction could be
due to an enhanced arginine consumption linked to high
arginase enzymatic activity [10]. Carnosine is able to
interfere with advanced glycosylated end-products for-
mation [11]. This action has been also demonstrated for
urea [12]. Recently a topical cream product containing
urea 5%, arginine and carnosine has been developed
(Ureadin Rx Db, Isdin Spain). This formulation, from a
theoretical point of view, is an interesting topical pro-
duct with a composition particularly suitable for the spe-
cific treatment of the xerotic skin in diabetic patients.
However, so far, not controlled clinical data are available
particular with a head-to-head comparison design with
standard topical emollient treatment. The aim of the
present study was to evaluate the efficacy of topical urea
(Ureadin Rx Db, ISDIN) containing also arginine and
carnosine, in comparison with glycerol-based (15%)Table 1 Patients characteristics at randomization, data presen
Variable UC group (n = 20)
Men/women 10/10
Age, years 66 (7)
History of Diabetes, years 14 (6)
Serum glucose mg/100 mL 153 (40)
DASI 1.7 (0.8)
VAS skin xerosis 6.1 (1.4)
Itching score (from 0 to 10) 8.5 (0.6)emollient topical product containing also vaseline (8%)
(Dexeryl, Pierre Fabre ) in the treatment of xerotic skin
in Type 2 diabetic patients.
Methods
Study design
The present study was a mono-centre prospective, parallel
group, randomised, assessor-blinded trial. Randomisation
list with a 1:1 ratio and with a block of 4 was generated
by the mean of statistical software (G-Power). Study trial
was registered in the Dutch Trials Register (trial num-
ber 3328). Local Institutional Review Board (Fitness
Metabolic ONLUS Monterotondo) approved the study
protocol. Study was performed between March 2011 and
February 2012.
Patient selection
Patients were enrolled in the trial after their written
informed consent according to the Declaration of Helsinki
[13]. Patients enrolled in this study were men and
women, aged between 40 and 75 years, with a con-
firmed diagnosis of type 2 diabetes and moderate-to-
severe foot xerosis, who had not used any topical moist-
urizers on their feet for at least 2 weeks. Insulin-
dependent diabetes mellitus, presence of foot lesions
and peripheral arterial diseases were the main exclusion
criteria. We assessed the effect of urea 5% cream (UC)
containing also arginine and carnosine on skin hydra-
tion in 40 type 2 diabetic patients treated with UC or
the comparator (EC) for 28 days with a twice-daily ap-
plication regimen. As comparator we have chosen a gly-
cerol, vaseline and liquid paraffin cream (Dexeryl)
which is commonly used as topical hydrating agent for
the treatment of skin xerosis. Both treatments were ap-
plied on the feet (dorsal and plantar regions) and in the
distal third of the leg.
Study outcomes
The principal outcomes of the trial were the Dryness
Area Severity Index (DASI) score, according to Serup
et al. [14], and the Visual Analogue Score (VAS) for skin
dryness evaluated at baseline and at the end of studyted as mean (SD)


















Not meeting inclusion criteria (n=25)
Declined to participate (n=13)
Figure 1 Study flow diagram.
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(GF). The DASI score evaluates dry skin using a 5-point
Likert scale ranging from 0 (=no dryness) to 4 (=severe
dryness). We used a visual analogue scales (VAS) for sub-
jective evaluation of dryness of the skin; the results were












Figure 2 Evolution of DASI score (mean values) from baseline at wee
Lower scores mean reduction in xerosis.skin dryness and 10 the best skin hydration state imagi-
nable. Secondary endpoints of the study were the per-
centage reduction of DASI score in comparison with
baseline values and the evolution of patient-assessed itch
sensation according to Hagermark [15] with a scale from
0 (extreme itch sensation) to 10 (not itch).week 4
UC EC














Figure 3 Evolution of VAS score (means values) for skin xerosis from baseline at week 2 and week 4 in UC treated patients and EC
treated group. High score means less xerosis.
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Statistical analyses were performed using SPSS statistical
software (ver. 13.0). Data were expressed as mean (SD). All
P values were two-sided. The present trial was designed as
a superiority trial. The power calculation assumed a differ-
ence between the two treatments in the DASI score at week
4 of at least 1.1 points with an effect size of 0.6. This as-
sumption provided 90% power at an alpha level of .05 (two-
tailed test) for a sample size of at least 40 evaluable patients
in total. Sample size calculation was performed using
G*Power program Ver.3.03 (Kiel, Germany). Two-tailed
unpaired T-test, two-tailed Mann–Whitney (unpaired) and
Wilcoxon (paired) tests were applied to compare treat-
ments and to compare baseline levels with values at the
end of study period. The analysis was based on the
intention-to- treat principle and involved all patients who
were randomly assigned to the treatments. A P value








Figure 4 Evolution of Itch score (IS) (means values) from
baseline at week 2 and week 4 in UC treated patients and EC
treated group. High score means less itch.Results
A total of 78 patients were screened for inclusion in the
study. A total of 40 patients, fulfilling inclusion and ex-
clusion criteria were enrolled: 20 were randomised to
UC and 20 to EC group. Table 1 shows the patients
characteristics at baseline. Main characteristics at ran-
domisation were similar in the two groups even if there
werea significative differences in patients randomised to
UC in comparison to EC group regarding age, duration
of diabetes and baseline VAS scores mean values. All
patients concluded the 4-week treatment period. Figure 1
shows the study flowchart. UC induced a significantly
greater hydration than the glycerol-based emollientcream: in UC group DASI score was reduced from 1.7 at
baseline to 0.2 at week 4 ( p < 0.001; Wilcoxon test, a
percentage reduction of 89%); in the EC group DASI
score was reduced from 1.9 to 1.0 at week 4, a 47% per-
centage reduction in comparison with baseline values.
After 4 weeks, compared with the control group, mean
DASI score in UC treated group was significantly lower
(0.2 vs. 1.0; p = 0.048, unpaired T-test) (Figure 2). Me-
dian values of DASI score were 1.5 in UC group and 2
in EC at baseline. At week 4 median DASI scores were 0
for UC group and 1 in EC group, respectively (p = 0.0005
Mann–Whitney test). Mean VAS score significantly
improved in both groups during treatment. Mean VAS
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higher in UC group in comparison with the control
group (9.8 vs. 8.2; p = 0.05, unpaired T-Test) (Figure 3).
Median values of VAS score were 6 in UC group and 7
in EC at baseline. At week 4 median VAS scores were 10
for UC group and 9 in EC group, respectively(p = 0.0001
Mann–Whitney test). Mean Itching score (IS) at baseline
were 8.5 in UC and 9.3 in EC group. At week 4, mean IS
increased significantly (P = 0.05, Wilcoxon test) in UC to
9.9 in comparison to baseline. In EC group mean IS
score was 9.7 at week 4. No differences were observed in
the two groups at week 4 (Figure 4).
Discussion
Diabetes mellitus induces many pathophysiologic
changes in the skin [16]. Diabetes also induces increase
in the dermis of advanced glycosylation end products
(AGEs), which may be responsible for some skin
changes in persons with elevated blood sugars [17].
Xerosis (with prevalence higher than 40%) with pruritus
and scleroderma-like skin changes are the most com-
monly observed cutaneous manifestations of this com-
mon disease [18]. Xerosis of the diabetic foot could
promote ulceration through the development of fissures
and hyperkeratosis. Its treatment is therefore important
and must be implemented early on. Skin xerosis is com-
monly treated with the repeated use of emollients and
moisturizers [19]. Their use is based on sound evidence
of the importance of maintaining the skin's water con-
tent. Emollient products could vary in term of beneficial
effects on the skin [20]. Recent data have shown that
topical urea can act not only as a simple hydrating mo-
lecule but in addition it could be able to improve cell
differentiation of keratinocytes. In a randomized placebo
controlled trial Garrigue [21] et al. have shown that top-
ical urea 5% is able to improve xerosis in the diabetic
foot by 61% after 4 weeks of treatment. In our study we
compared urea, arginine and carnosine topical product
with a standard treatment reference (Dexeryl). Reduction
of xerosis score observed in our trial was 90% in the UC
group. This clinical effect could be due to the particular
composition of UC. Urea and carnosine could favourably
interfere with formation and accumulation of advanced
glycated end-products [22]. Topical urea is able to in-
crease the synthesis of aquaporin in keratinocytes there-
fore increasing the hydration of the skin [6]. Arginine
supplementation improves microcirculation in diabetes
[23]. Therefore UC composition could have a strong
rational as an “active” emollient for the treatment of
skin xerosis observed in diabetic patients.
Conclusion
Our study has shown that application of urea 5% asso-
ciated with arginine and carnosine cream increase skinhydration and alleviate the condition of skin dryness in
Type 2 diabetic patients in comparison with a control
glycerol-based emollient product. Some limitations
should be considered in evaluating our results. First this
study was not double-blind. The main difficulty in per-
forming a double-blind trial in this setting was linked to
the different formulations and texture of the study pro-
ducts. Therefore we decided to perform an assessor-
blinded evaluation of the primary endpoint of the study.
A second limitation of our study is that we have eva-
luated as primary endpoint a subjective clinical assess-
ment parameters (DASI score and the VAS) instead of
an instrumental objective variable. However the main
therapeutic goal of emollient treatment in diabetes is to
obtain an increase in hydration of the skin clinically eva-
luable. Further studies are necessary to evaluate if the
treatment with this topical product could be associated
with improvement in microcirculation and/or modifica-
tion of skin structure in diabetes.
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